An updated analysis by KEYNOTE-024 revealed that the 5-year survival rate of NSCLC patients treated with immunotherapy increased to 30%,1 providing further evidence for using anti-PD-(L)1 antibody in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.